Neoplasms, Nerve Tissue: Clinical Trials

1,378 trials for Neoplasms, Nerve Tissue, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1378 completed. 1378 Phase 1, 387 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11378Completed 1378
Phase 2387Completed 387

Follow Neoplasms, Nerve Tissue: new trials by email Literature Review of Neoplasms, Nerve Tissue trials Research Report on Neoplasms, Nerve Tissue

Trials (filtered) newest first · largest first

All 1,378 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
MK-4700, Pembrolizumab - Malignant Neoplasm
Phase 1CompletedMerck Sharp & Dohme LLC52025-04-232026-03-16
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT), Photon Emission Tomography / CT (PET/CT), 64Cu-Dotatate - Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor
Phase 1CompletedUniversity of Wisconsin, Madison42025-03-072026-06-23
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
5-Aminolevulinic acid Hydrochloride (Gliolan®), CV01 - Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO)
Phase 1CompletedUniversität Münster162025-01-272026-02-27
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
B10 L-BPA Injection - Meningioma, Boron Neutron Capture Therapy
Phase 1 / Phase 2CompletedHeron Neutron Medical Corp.102024-10-142026-05-11
Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma
123I-ATT001 - Glioma Glioblastoma Multiforme
Phase 1CompletedTheragnostics Ltd72024-07-042026-03-31
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
FYB206, Keytruda - Melanoma, Stage II, Melanoma Stage III
Phase 1CompletedFormycon AG962024-07-012026-10-20
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
GME751, Keytruda - EU, Keytruda - US - Melanoma
Phase 1CompletedSandoz3222024-05-152026-07-07
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
AMG 355, Pembrolizumab - Advanced Solid Tumors
Phase 1CompletedAmgen772024-03-072026-08-11
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser - Neurofibromatosis 1
Phase 1CompletedMassachusetts General Hospital132024-03-012025-11-21
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
IMM-6-415 - Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma
Phase 1 / Phase 2CompletedImmuneering Corporation302024-02-272025-05-28
Study of DF6215 in Patients With Advanced Solid Tumors
DF6215, pembrolizumab, KEYTRUDA® - Solid Tumor, Adult, Solid Tumor Cancer
Phase 1CompletedDragonfly Therapeutics352023-11-282026-03-18
A Study of GC101 TIL in Advanced Melanoma (BZ)
GC101 TIL - Tumor Infiltrating Lymphocytes, Safety
Phase 1 / Phase 2CompletedShanghai Juncell Therapeutics182023-11-082025-12-23
Intratumoral PH-762 for Cutaneous Carcinoma
PH-762 - Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin
Phase 1CompletedPhio Pharmaceuticals Inc.222023-11-072026-09-21
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg - Glioblastoma
Phase 1 / Phase 2CompletedCantex Pharmaceuticals332023-09-052026-10-19
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
ITI-1001 - Glioblastoma
Phase 1CompletedImmunomic Therapeutics, Inc.102023-08-212026-07-01
TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
TN-TC11G, Temozolomide Oral Product, Radiotherapy - Glioblastoma
Phase 1 / Phase 2CompletedGrupo Español de Investigación en Neurooncología332023-08-182026-02-12
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 - Melanoma, Non Small Cell Lung Cancer
Phase 1CompletedOncoC4, Inc.182023-07-112026-09-14
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
CV09050101 mRNA vaccine (CVGBM) 12 μg, CV09050101 mRNA vaccine (CVGBM) 25 μg, CV09050101 mRNA vaccine (CVGBM) 50 μg - Glioblastoma
Phase 1CompletedCureVac372023-06-012026-02-18
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor
Phase 1 / Phase 2CompletedSensei Biotherapeutics, Inc.982023-05-312026-09-02
A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.
PRRT with 177Lu-DOTATATE - Neuroblastoma
Phase 1CompletedInstitut Claudius Regaud12023-04-172026-04-29

Showing 20 of 1378. Sign in to see all of them.

Narrower conditions

Melanoma (579)  ·  Glioblastoma (408)  ·  Glioma (241)  ·  Brain Neoplasms (229)  ·  Astrocytoma (207)  ·  Gliosarcoma (175)  ·  Neoplasms (150)  ·  Central Nervous System Neoplasms (143)  ·  Neuroblastoma (142)  ·  Oligodendroglioma (135)  ·  Carcinoma, Non-Small-Cell Lung (132)  ·  Breast Neoplasms (104)  ·  Carcinoma, Renal Cell (101)  ·  Sarcoma (89)  ·  Medulloblastoma (84)

Broader conditions

Neoplasms by Histologic Type (1374)  ·  Neuroectodermal Tumors (1340)  ·  Neoplasms, Germ Cell and Embryonal (1334)  ·  Neoplasms (1228)  ·  Neoplasms by Site (996)  ·  Neoplasms, Glandular and Epithelial (884)  ·  Neoplasms, Neuroepithelial (718)  ·  Neuroendocrine Tumors (636)  ·  Skin and Connective Tissue Diseases (615)  ·  Skin Diseases (613)  ·  Nevi and Melanomas (593)  ·  Skin Neoplasms (565)  ·  Nervous System Diseases (381)  ·  Nervous System Neoplasms (346)

Interventions

Temozolomide (122)  ·  pembrolizumab (75)  ·  Radiotherapy (70)  ·  Nivolumab (58)  ·  Ipilimumab (56)  ·  Cyclophosphamide (54)  ·  Bevacizumab (36)  ·  aldesleukin (36)  ·  Filgrastim (35)  ·  Carboplatin (34)  ·  Radiation (34)  ·  Interleukin-2 (30)  ·  Irinotecan (28)  ·  Cisplatin (24)  ·  Everolimus (21)

Sponsors

National Cancer Institute (NCI) (149)  ·  Memorial Sloan Kettering Cancer Center (34)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (31)  ·  M.D. Anderson Cancer Center (29)  ·  Novartis Pharmaceuticals (25)  ·  Hoffmann-La Roche (22)  ·  Duke University (21)  ·  Dana-Farber Cancer Institute (19)  ·  St. Jude Children's Research Hospital (18)  ·  Children's Oncology Group (17)  ·  H. Lee Moffitt Cancer Center and Research Institute (17)  ·  Merck Sharp & Dohme LLC (16)  ·  New Approaches to Neuroblastoma Therapy Consortium (15)  ·  Jonsson Comprehensive Cancer Center (14)  ·  Fred Hutchinson Cancer Center (12)

Countries

United States (1090)  ·  France (93)  ·  Canada (89)  ·  Spain (87)  ·  Australia (83)  ·  Germany (82)  ·  United Kingdom (63)  ·  Italy (52)  ·  Netherlands (52)  ·  Switzerland (43)  ·  Belgium (39)  ·  China (32)  ·  Japan (24)  ·  South Korea (23)  ·  Denmark (22)

Top investigators

Darell D. Bigner, MD, PhD (6)  ·  F. Stephen Hodi, MD (6)  ·  Steven A. Rosenberg, MD, PhD (6)  ·  Craig L. Slingluff, MD (5)  ·  David A. Reardon, MD (5)  ·  Henry S. Friedman, MD (5)  ·  Michael Prados, MD (5)

Results publications

PMID 31401903, PMID 32747469, PMID 22256804, PMID 23377664, PMID 23545055, PMID 23676418, PMID 24577748, PMID 24983357, PMID 25837513, PMID 32078016, PMID 32350119, PMID 34311780, PMID 36648215, PMID 39504507, PMID 41920422, PMID 10394416, PMID 10797354, PMID 10811235, PMID 10890744, PMID 11410496, PMID 11595689, PMID 11705489, PMID 11874634, PMID 12039921, PMID 12528778, PMID 12573762, PMID 12576434, PMID 12721262, PMID 12749708, PMID 12749710, PMID 12833467, PMID 12947072, PMID 12957454, PMID 14577912, PMID 14670747, PMID 14767498, PMID 14769136, PMID 14769140, PMID 15010069, PMID 15033677, PMID 15292713, PMID 15592836, PMID 15667958, PMID 15696196, PMID 15758009, PMID 15814645, PMID 15937544, PMID 15944250, PMID 16012795, PMID 16061868

NIH funding

2016 (15), U01CA081457 (13), 2019 (12), 2023 (12), P01CA081403 (12), U01CA097452 (10), UM1CA097452 (10), P30CA008748 (9), U01CA062475 (9), 2014 (8), 2018 (8), 2009 (7), 2017 (7), U10CA025224 (7), P30CA015083 (6)